Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:21 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
NCT02689219 · Nabil Adra · PHASE2 · terminated · last registry update 2019-12-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “lack of funding/ benefit” | – | Registry record, Nabil Adra |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TUBB4B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-16Phase 3 first posted: National Cancer Institute (NCI), Cisplatin + Doxorubicin Hydrochloride (NCT04628767)
- 2020-10-08Phase 3 first posted: National Cancer Institute (NCI), Docetaxel + Eribulin Mesylate (NCT04579224)
- 2020-10-06Phase 3 first posted: National Cancer Institute (NCI), Selumetinib Sulfate + Vinblastine Sulfate (NCT04576117)
- 2020-08-28Phase 3 first posted: National Cancer Institute (NCI), Blinatumomab + Cyclophosphamide (NCT04530565)
- 2020-08-28Phase 3 first posted: Acerta Pharma BV, acalabrutinib + placebo (NCT04529772)
- 2020-05-22Phase 3 first posted: RemeGen Co., Ltd., RC48-ADC + Paclitaxel Injection (NCT04400695)
- 2020-03-13Phase 3 first posted: Mats Heyman, Omitted Doxorubicin + Omitted Vincristine+Dexamethasone pulses (NCT04307576)
- 2019-11-18Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Selumetinib Sulfate (NCT04166409)
- 2019-06-13Phase 3 first posted: National Cancer Institute (NCI), Cyclophosphamide + Doxorubicin Hydrochloride (NCT03984448)
- 2019-05-22Phase 3 first posted: Children's Oncology Group, Blinatumomab + Calaspargase Pegol (NCT03959085)
- 2019-04-23Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Enfortumab Vedotin (NCT03924895)
- 2019-04-16Phase 3 first posted: National Cancer Institute (NCI), Asparaginase Erwinia chrysanthemi + Blinatumomab (NCT03914625)
- 2019-04-09Phase 3 first posted: National Cancer Institute (NCI), Brentuximab Vedotin + Dacarbazine (NCT03907488)
- 2019-03-12Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Selumetinib Sulfate (NCT03871257)
- 2019-01-30Results posted on the registry: St. Jude Children's Research Hospital, Induction Chemotherapy + Low-Risk Therapy (NCT00602667)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision